ArticlePharmaceutics2020
Enhanced Viability of Probiotics against Gastric Acid by One-Step Coating Process with Poly-L-Lysine: In Vitro and In Vivo Evaluation.
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 23 citations in OpenAlex.
- Cordyceps Militaris Exopolysaccharides and Lactiplantibacillus Plantarum H8 Synergistically Improve Immune Function Damage in Cyclophosphamide-Induced Immunosuppressed Mice.Probiotics and antimicrobial proteins · 2026Article
- "Single-Cell Encapsulation of Lactiplantibacillus Plantarum Via Layer-by-Layer Technique for Enhanced Viability and Shelf Life: Insights on Multilayer Assembly on Bacteria".Macromolecular bioscience · 2026Article
- Polymer-Based and Biomaterial Encapsulation of Probiotics for Improved Viability.Probiotics and antimicrobial proteins · 2026Review
- The challenges and strategies for navigatingTheranostics · 2026Review
- Circadian rhythms of gut microbiota and plaque vulnerability: mechanisms and chrono-microbiota modulation interventions.Gut microbes · 2025Review
- Synbiotic microencapsulation of Lactiplantibacillus plantarum-lentinan for enhanced growth in broilers.AMB Express · 2025Article
- Engineered probiotics for inflammatory bowel disease therapy: mechanisms, delivery strategies, and precision medicine.Frontiers in microbiology · 2025Review
- Dual-Responsive "Egg-Box" Shaped Microgel Beads Based on WFoods (Basel, Switzerland) · 2024Article
- Compositional Quality and Possible Gastrointestinal Performance of Marketed Probiotic Supplements.Probiotics and antimicrobial proteins · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Due to their low acid tolerance, a majority of probiotics face diculties with regard tosurviving in the gastric environment long enough to reach the intestinal surfaces where they colonizeand provide health benefits. We prepared a probiotic delivery system that can enhance their viabilityin acidic conditions by developing a one-step poly-L-lysine (PLL) coating process. We determinedwhether the coating process was successful by measuring the zeta potential and observing it withconfocal scanning microscopy. PLL-coated L. plantarum (PLL-LP), incubated in a solution of pH 2 for2 h, exhibited a higher viability (6.86 0.12 log CFU/mL of viable cells) than non-coated L. plantarum(non-coated LP), which exhibited only 2.7 1.23 log CFU/mL of viable cells. In addition, a higheramount of L. plantarum was detected in the feces of mice orally administered PLL-LP (6.2 0.4 logCFU/g of feces) than in the feces of the control groups. In addition to enhancing probiotic viability inpH 2 solution, the PLL coating showed no eect on the probiotic growth pattern and the viability ofeither freeze-dried L. plantarum or L. plantarum, stored at ?20 C and 4 C, respectively. Overall, theseresults indicated that the PLL coating is a promising potential probiotic delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.